Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths th...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

Ironbow Oct. 6 at 3:09 PM

$LUCD Dave / dmc / LPlates/ Dipsh!t 👇🏻🤡

0 · Reply

dmc4321 Oct. 6 at 3:02 PM

This is WRONG. $LUCD is a trade its not an investment. Why? Wall Street institutions are filled with experienced traders looking for any and every advantage. They are backed up by support staff that read and analyze EVERY SEC filing, and model EVERYTHING for EVERY diagnostic company. Then they back test it. We forecast this would happen, did it?, what did we miss, should we change our model. Rinse and repeat. So you must believe you and other retail investors in $LUCD or, $PAVM most of which do not even read the SEC filings, know more? Take BTIG's 2027 DCF Price Target of $2.50 for LUCD. BTIG's compliance department said the maximum value you can give to LUCD is $247.5 Million based on our internal models. So the analyst at the very end said its based on 99M shares being outstanding, even though there are 230M shares outstanding. Why not say 100M shares? because that would have exceeded their Model based on EVERY diagnostic test launch EVER and would have to be justified.

1 · Reply

edward103 Oct. 6 at 2:52 PM

$LUCD i really don’t care about a guy incessantly decrying a stock because he got killed in the name and now has made it his mission in life to belittle the co. Instead, ask yourself why a director bought over 400k shares at $1.30 (once there and then again another 100k at $1.0). Ask why the latest raise at $1 was oversubscribed. So do you want to take advice from a lunatic who has nothing to do but bash all day or from a director who just so happens to run a large hospital complex in Virginia? Who do you think has more insight into the possibilities?

1 · Reply

Elomee Oct. 6 at 1:46 PM

$LUCD https://www.gurufocus.com/news/3131272/ascendiant-capital-raises-price-target-for-lucid-diagnostics-lucd-lucd-stock-news

2 · Reply

oaksapollo Oct. 6 at 3:24 AM

$LUCD Alright, the start of the LCD window is this week. I think Thursday is the first potential time we could see a draft LCD, and the 2025 window goes from 10/9 to 11/6 (if nothing by 11/6, it's not happening this year). Just to recap for anyone new - ACG criteria yield a screening population of 30M people, and approximately half of them are CMS. So at $1938.01 (established CMS payment rate), that's a $29,000,000,000 ($29B) market opportunity with GUARANTEED PAYMENT (as soon as the government reopens) with no competition, and no other product like it. To quote Dr. Shaheen, EsoGuard is "a fundamental change in the care pathway." These are facts.

1 · Reply

NightSentiment Oct. 5 at 10:38 AM

$LUCD Technology services growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum.

0 · Reply

JRINPHX Oct. 3 at 9:15 PM

$LUCD Look what happened at $ICCM Today. They got their FDA approval and pricing. It was a sell the news event. I’m now worried that could be the case here. A big nothing burger.

6 · Reply

dmc4321 Oct. 3 at 8:17 PM

$LUCD @RetiredMD I tried to help you by posting the link to the Exact Science roundtable where they explained what it took to make ColoGuard successful. They actually approached LabCorp and Quest and were toldby both "We are not interested and if we were a deal would be structured where we took all the economic benefit". You have no clue about business or sales and marketing. Do you believe that LabCorp and/or Quest are not interested in the power dynamics and wont try and make as much as possible. Listen to the Exact roundtable and you will START to understand the challenge. https://wsw.com/webcast/baird80/register.aspx?conf=baird80&page=exas&url=https://wsw.com/webcast/baird80/exas/1922154 Do you think that all the diagnostic companies after getting CMS approval have not tried everything. Failure is nearly certain. You need large resourses to dedicate to Sales and Marketing over MULTIPLE years. With 230M shares outstanding $LUCD will be broke AGAIN this coming Summer and need to add ANOTHER 100M + shares so 330M+ shares or $1.25 which is BTIG's 2027 target or $415 Market Cap.

1 · Reply

dmc4321 Oct. 3 at 8:13 PM

$LUCD So you said you would ask the questions I gave you after you asked for questions. But you didnt, because if you did you would not be happy with your position.

0 · Reply

PortfolioMgmt23 Oct. 3 at 8:04 PM

$LUCD I had a great conversation this week on Lucid and feel very good about my position. Currently sitting at 213k shares and may add another 20k. You do what’s right for you and your family. This position is right for me and mine. Dave, god bless you. You aren’t changing anyone’s mind. All in.

2 · Reply

Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

Sep 16, 2025, 8:01 AM EDT - 21 days ago

Market Cap	138.82M
Revenue (ttm)	4.35M
Net Income (ttm)	-45.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,046.67%
Debt to Equity Ratio	3.22

Volume	1,477,400
Avg Vol	1,192,492
Day's Range	N/A - N/A
Shares Out	133.48M
Stochastic %K	43%
Beta	1.19
Analysts	Strong Sell
Price Target	$3.71